<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00308620</url>
  </required_header>
  <id_info>
    <org_study_id>0510M77007</org_study_id>
    <nct_id>NCT00308620</nct_id>
  </id_info>
  <brief_title>Investigating the Anti-Human Immunodeficiency Virus (HIV) &amp; Anti-inflammatory Effect of Chloroquine</brief_title>
  <official_title>A Randomized, Pilot Study of the Anti-Viral and Anti-Inflammatory Effects of Chloroquine in Early HIV Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Minnesota - Clinical and Translational Science Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Minnesota Medical Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Minnesota - Clinical and Translational Science Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Summary: Chloroquine is a medication that in laboratory settings has significant anti-HIV
      effects in HIV infected T-cells. Chloroquine has been used safely for over 60 years for
      malaria treatment and prevention, and it also has significant anti-inflammatory effects. No
      formal study of chloroquine has been performed in people with HIV infection. Chloroquine is
      used worldwide and is quite inexpensive outside of the United States. If shown to be
      effective, chloroquine could be a very important tool worldwide in delaying HIV disease
      progression which would extend the time period without needing anti-retroviral therapy. In
      countries where anti-retroviral therapy is not available, this could be very helpful.

      This is an 8 week trial study requiring 3 study visits. Participants will be ask to take a
      once a day study medication (chloroquine or placebo) for 8 weeks and have three blood draws
      for CD4 counts, HIV viral loads, and other research tests. The visits are at study
      enrollment, 4 weeks, and 8 weeks.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Summary:

      A phase I randomized, double-blind, placebo controlled trial to investigate the efficacy of
      chloroquine to decrease T-cell activation and decrease viral load in early HIV.

      Scientific Rationale:

      Chloroquine has in vivo direct anti-HIV effects and an anti-inflammatory effect. These
      properties may be beneficial in reducing viral burden and immune activation therefore
      delaying HIV disease progression.

      Sample Size: 25

      Length of Study: 8 weeks, [enrollment + 2 follow up visits].

      Intervention:

        -  Arm 1a: Chloroquine 250mg orally once daily for 8 weeks.

        -  Arm 1b: Chloroquine 500mg orally once daily for 8 weeks.

        -  Arm 2: Placebo once daily for 8 weeks.

      Measurements:

        -  Blood draws at weeks: 0, 4, and 8 weeks.

        -  CD4, viral load measurements will be communicated to the referring provider (with
           subject consent).
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Insufficient financial support; lack of efficacy for primary endpoint
  </why_stopped>
  <start_date>March 2006</start_date>
  <completion_date type="Actual">June 2009</completion_date>
  <primary_completion_date type="Actual">December 2008</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>HIV Viral Load Change</measure>
    <time_frame>baseline and 8 weeks</time_frame>
    <description>HIV-1 viral load change between baseline and 8 weeks</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Immune Activation Assessed by Flow Cytometry Analysis From Baseline to 8 Weeks</measure>
    <time_frame>8 weeks</time_frame>
    <description>The Change in the percentages of CD38+ HLA-DR+ CD8 and CD4 memory T cells from baseline to 8 weeks.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">13</enrollment>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>Chloroquine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Chloroquine 205mg or 500mg orally once daily (Results pooled)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo once daily for 8 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>chloroquine phosphate</intervention_name>
    <description>250mg or 500mg PO (by mouth) QDay</description>
    <arm_group_label>Chloroquine</arm_group_label>
    <other_name>Aralen</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo once daily for 8 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  HIV-1 infected adults

          -  CD4 count &gt; 250 cells/mm3

          -  Not presently receiving HIV antiretroviral therapy (&gt; 6 months or naïve)

          -  Viral load &gt; 3000 RNA copies/mL (3.5 log)

          -  No planned HIV anti-retroviral therapy for 8 weeks

        Exclusion Criteria:

          -  Prior retinal eye disease

          -  CD4 &lt; 250 cells/µL

          -  Renal failure

          -  Active malignancy

          -  Corticosteroid therapy

          -  Age &lt; 18 or &gt; 65 years
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David R Boulware, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Minnesota - Clinical and Translational Science Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Minnesota ACTU</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://cvp.umn.edu</url>
    <description>University of Minnesota Clinical Virology Program</description>
  </link>
  <results_reference>
    <citation>Murray SM, Down CM, Boulware DR, Stauffer WM, Cavert WP, Schacker TW, Brenchley JM, Douek DC. Reduction of immune activation with chloroquine therapy during chronic HIV infection. J Virol. 2010 Nov;84(22):12082-6. doi: 10.1128/JVI.01466-10. Epub 2010 Sep 15.</citation>
    <PMID>20844049</PMID>
  </results_reference>
  <verification_date>May 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 27, 2006</study_first_submitted>
  <study_first_submitted_qc>March 27, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 29, 2006</study_first_posted>
  <results_first_submitted>September 26, 2011</results_first_submitted>
  <results_first_submitted_qc>July 9, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 17, 2012</results_first_posted>
  <last_update_submitted>July 9, 2012</last_update_submitted>
  <last_update_submitted_qc>July 9, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 17, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HIV</keyword>
  <keyword>chloroquine</keyword>
  <keyword>disease progression</keyword>
  <keyword>inflammation</keyword>
  <keyword>treatment naive</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chloroquine diphosphate</mesh_term>
    <mesh_term>Anti-Inflammatory Agents</mesh_term>
    <mesh_term>Chloroquine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>2006-2008 recruitment of volunteers in HIV care but electing to not receive ART.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Chloroquine 500mg</title>
          <description>Chloroquine 500mg PO once daily x 8 weeks</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Placebo once daily for 8 weeks</description>
        </group>
        <group group_id="P3">
          <title>Chloroquine 250mg</title>
          <description>Chloroquine 250mg PO once daily x 8 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Chloroquine 500mg</title>
          <description>Chloroquine 500mg PO once daily x 8 weeks</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Placebo once daily for 8 weeks</description>
        </group>
        <group group_id="B3">
          <title>Chloroquine 250mg</title>
          <description>Chloroquine 250mg PO once daily x 8 weeks</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="3"/>
            <count group_id="B2" value="4"/>
            <count group_id="B3" value="6"/>
            <count group_id="B4" value="13"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40" spread="15"/>
                    <measurement group_id="B2" value="34" spread="5"/>
                    <measurement group_id="B3" value="36" spread="5"/>
                    <measurement group_id="B4" value="36.5" spread="8.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>HIV Viral Load Change</title>
        <description>HIV-1 viral load change between baseline and 8 weeks</description>
        <time_frame>baseline and 8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Chloroquine 250mg or 500mg</title>
            <description>Chloroquine 250mg or 500mg orally once daily x 8 weeks. n=6 for 250mg; n=3 for 500mg</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo orally once daily for 8 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>HIV Viral Load Change</title>
          <description>HIV-1 viral load change between baseline and 8 weeks</description>
          <units>log10 copies/mL</units>
          <param>Log Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-.083" spread=".5"/>
                    <measurement group_id="O2" value="0.0" spread=".1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Immune Activation Assessed by Flow Cytometry Analysis From Baseline to 8 Weeks</title>
        <description>The Change in the percentages of CD38+ HLA-DR+ CD8 and CD4 memory T cells from baseline to 8 weeks.</description>
        <time_frame>8 weeks</time_frame>
        <population>Analysis of Chloroquine arms is pooled.</population>
        <group_list>
          <group group_id="O1">
            <title>Chloroquine 250mg or 500mg</title>
            <description>Chloroquine 500mg orally once daily x 8 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo orally once daily for 8 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Immune Activation Assessed by Flow Cytometry Analysis From Baseline to 8 Weeks</title>
          <description>The Change in the percentages of CD38+ HLA-DR+ CD8 and CD4 memory T cells from baseline to 8 weeks.</description>
          <population>Analysis of Chloroquine arms is pooled.</population>
          <units>percentage change</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>CD8 CD38+HLA-DR+</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.5" lower_limit="-7" upper_limit="2"/>
                    <measurement group_id="O2" value="1.85" lower_limit="-3" upper_limit="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD4 ki67+</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.0" lower_limit="-3" upper_limit="2"/>
                    <measurement group_id="O2" value="1.4" lower_limit="-0.5" upper_limit="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Chloroquine 500mg</title>
          <description>Chloroquine 500mg PO once daily x 8 weeks</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo once daily for 8 weeks</description>
        </group>
        <group group_id="E3">
          <title>Chloroquine 250mg</title>
          <description>Chloroquine 250mg PO once daily x 8 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Social circumstances</title>
            <event_list>
              <event>
                <sub_title>Death (non-related)</sub_title>
                <description>Autopsy Report</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>David Boulware</name_or_title>
      <organization>University of Minnesota</organization>
      <phone>6126269546</phone>
      <email>boulw001@umn.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

